Randomized Placebo-Controlled Trial of Long-Term Treatment with Sibutramine in Mild to Moderate Obesity

Journal of Family Practice, June, 2001 by Ian G. Smith, Michael A. Goulder

[ILLUSTRATION OMITTED]

TABLE 1
CHARACTERISTICS AT SCREENING OF PATIENTS WHO ENTERED
THE DOUBLE-BLIND PHASE

                                             Treatment Group

Characteristic                                  Placebo(*)

Mean age [  or -] SD, years (range)      41.9 [  or -] 11.6 (20-65)
Sex: men, women; no.                                        32, 131
Race: white, other; no.                                      161, 2
Mean height [  or -] SD, cm (range)    165.3 [  or -] 8.6 (144-189)
Median weight, kg (range)                               87 (63-136)
Mean BMI [  or -] SD, kg/[m.sup.2]
  (range)                             32.4 [  or -] 3.5 (27.0-40.0)
Cholesterol, mmol/L                                            5.52
Triglycerides, mmol/L                                          2.20
Glocuse, mmol/L                                                 5.6
Family history of obesity, no. (%)                      89/161 (55)
Mean age at onset, year (range)                           26 (1-62)
Previous attempt at weight loss,
  no. (%)                                              129/163 (79)
Lost weight at previous attempt,
  no. (%)                                               91/127 (72)
Treated cardiovascular condition,
  no. (%)                                                13/163 (8)

                                             Treatment Group

Characteristic                         Sibutramine 10 mg([dagger])

Mean age [  or -] SD, years (range)      41.0 [  or -] 12.1 (19-65)
Sex: men, women; no.                                        33, 128
Race: white, other; no.                                      161, 0
Mean height [  or -] SD, cm (range)    164.3 [  or -] 8.8 (148-193)
Median weight, kg (range)                               87 (60-134)
Mean BMI [  or -] SD, kg/[m.sup.2]
  (range)                             32.9 [  or -] 4.1 (25.2-43.6)
Cholesterol, mmol/L                                               6
Triglycerides, mmol/L                                          2.08
Glocuse, mmol/L                                                 5.4
Family history of obesity, no. (%)                      85/161 (53)
Mean age at onset, year (range)                           25 (3-60)
Previous attempt at weight loss,
  no. (%)                                              123/161 (76)
Lost weight at previous attempt,
  no. (%)                                               90/123 (73)
Treated cardiovascular condition,
  no. (%)                                                10/161 (6)

                                             Treatment Group

Characteristic                         Sibutramine 15 mg([dagger])

Mean age [  or -] SD, years (range)      42.7 [  or -] 11.7 (21-65)
Sex: men, women; no.                                        30, 131
Race: white, other; no.                                       159.2
Mean height [  or -] SD, cm (range)    163.8 [  or -] 8.5 (146-188)
Median weight, kg (range)                               87 (64-128)
Mean BMI [  or -] SD, kg/[m.sup.2]
  (range)                             32.7 [  or -] 3.3 (27.2-39.8)
Cholesterol, mmol/L                                            5.58
Triglycerides, mmol/L                                          2.10
Glocuse, mmol/L                                                 5.5
Family history of obesity, no. (%)                      93/161 (58)
Mean age at onset, year (range)                           26 (0-64)
Previous attempt at weight loss,
  no. (%)                                              119/160 (74)
Lost weight at previous attempt,
  no. (%)                                               87/117 (74)
Treated cardiovascular condition,
  no. (%)                                                13/161 (8)

SD denotes standard deviation; BMI, body mass index (body weight in
kg divided by the square of the height in meters).

(*) N = 163.

([dagger]) N=161.